Global Radiopharmaceuticals in Nuclear Medicine Market Research Report 2024(Status and Outlook)
Report Overview:
Radiopharmaceuticals are used in the field of nuclear medicine as radioactive tracers in medical imaging and in therapy for many diseases. Many radiopharmaceuticals use technetium-99m (Tc-99m) which has many useful properties as a gamma-emitting tracer nuclide.
The Global Radiopharmaceuticals in Nuclear Medicine Market Size was estimated at USD 5225.65 million in 2023 and is projected to reach USD 7002.88 million by 2029, exhibiting a CAGR of 5.00% during the forecast period.
This report provides a deep insight into the global Radiopharmaceuticals in Nuclear Medicine market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Radiopharmaceuticals in Nuclear Medicine Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Radiopharmaceuticals in Nuclear Medicine market in any manner.
Global Radiopharmaceuticals in Nuclear Medicine Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
Bracco Imaging S.P.A.
Cambridge Isotope Laboratories, Inc.
Cardinal Health, Inc.
Covidien, Plc
Eczacibasi-Monrol
Fujifilm Holdings Corporation
GE Healthcare (Subsidiary Of General Electric Company)
IBA Group
Isotec, Inc. (Sigma-Aldrich)
Lantheus Medical Imaging, Inc.
Nordion, Inc.
Ntp Radioisotopes (Pty), Ltd.
Siemens Healthcare (Subsidiary Of Siemens AG)
Taiyo Nippon Sanso Corporation
Urenco Limited
Rotem Industries, Ltd., Inc.
Australian Nuclear Association And Technology Organization (ANSTO)
Board of Radiation And Isotope Technology (BRIT)
Institute of Atomic Energy Polatom Radioisotope Centre
Institute of Isotopes Co., Ltd.
Institute Of Radioelement (IRE)
Market Segmentation (by Type)
Diagnostic Radiopharmaceuticals
Therapy Radiopharmaceuticals
Enriched Stable Isotopes
Market Segmentation (by Application)
Diagnostic Application
Therapeutic Application
Research
Pharmaceutical
Other
Geographic Segmentation
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Note: this report may need to undergo a final check or review and this could take about 48 hours.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Radiopharmaceuticals in Nuclear Medicine Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the Market's Competitive Landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.
Chapter 12 is the main points and conclusions of the report.
Radiopharmaceuticals are used in the field of nuclear medicine as radioactive tracers in medical imaging and in therapy for many diseases. Many radiopharmaceuticals use technetium-99m (Tc-99m) which has many useful properties as a gamma-emitting tracer nuclide.
The Global Radiopharmaceuticals in Nuclear Medicine Market Size was estimated at USD 5225.65 million in 2023 and is projected to reach USD 7002.88 million by 2029, exhibiting a CAGR of 5.00% during the forecast period.
This report provides a deep insight into the global Radiopharmaceuticals in Nuclear Medicine market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Radiopharmaceuticals in Nuclear Medicine Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Radiopharmaceuticals in Nuclear Medicine market in any manner.
Global Radiopharmaceuticals in Nuclear Medicine Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
Bracco Imaging S.P.A.
Cambridge Isotope Laboratories, Inc.
Cardinal Health, Inc.
Covidien, Plc
Eczacibasi-Monrol
Fujifilm Holdings Corporation
GE Healthcare (Subsidiary Of General Electric Company)
IBA Group
Isotec, Inc. (Sigma-Aldrich)
Lantheus Medical Imaging, Inc.
Nordion, Inc.
Ntp Radioisotopes (Pty), Ltd.
Siemens Healthcare (Subsidiary Of Siemens AG)
Taiyo Nippon Sanso Corporation
Urenco Limited
Rotem Industries, Ltd., Inc.
Australian Nuclear Association And Technology Organization (ANSTO)
Board of Radiation And Isotope Technology (BRIT)
Institute of Atomic Energy Polatom Radioisotope Centre
Institute of Isotopes Co., Ltd.
Institute Of Radioelement (IRE)
Market Segmentation (by Type)
Diagnostic Radiopharmaceuticals
Therapy Radiopharmaceuticals
Enriched Stable Isotopes
Market Segmentation (by Application)
Diagnostic Application
Therapeutic Application
Research
Pharmaceutical
Other
Geographic Segmentation
- North America (USA, Canada, Mexico)
- Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
- South America (Brazil, Argentina, Columbia, Rest of South America)
- The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the Radiopharmaceuticals in Nuclear Medicine Market
- Overview of the regional outlook of the Radiopharmaceuticals in Nuclear Medicine Market:
- Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
- This enables you to anticipate market changes to remain ahead of your competitors
- You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
- The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
- Provision of market value (USD Billion) data for each segment and sub-segment
- Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
- Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
- Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
- Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
- The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
- Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis
- Provides insight into the market through Value Chain
- Market dynamics scenario, along with growth opportunities of the market in the years to come
- 6-month post-sales analyst support
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Note: this report may need to undergo a final check or review and this could take about 48 hours.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Radiopharmaceuticals in Nuclear Medicine Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the Market's Competitive Landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.
Chapter 12 is the main points and conclusions of the report.
1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE
1.1 Market Definition and Statistical Scope of Radiopharmaceuticals in Nuclear Medicine
1.2 Key Market Segments
1.2.1 Radiopharmaceuticals in Nuclear Medicine Segment by Type
1.2.2 Radiopharmaceuticals in Nuclear Medicine Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Radiopharmaceuticals in Nuclear Medicine Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global Radiopharmaceuticals in Nuclear Medicine Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET COMPETITIVE LANDSCAPE
3.1 Global Radiopharmaceuticals in Nuclear Medicine Sales by Manufacturers (2019-2024)
3.2 Global Radiopharmaceuticals in Nuclear Medicine Revenue Market Share by Manufacturers (2019-2024)
3.3 Radiopharmaceuticals in Nuclear Medicine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Radiopharmaceuticals in Nuclear Medicine Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Radiopharmaceuticals in Nuclear Medicine Sales Sites, Area Served, Product Type
3.6 Radiopharmaceuticals in Nuclear Medicine Market Competitive Situation and Trends
3.6.1 Radiopharmaceuticals in Nuclear Medicine Market Concentration Rate
3.6.2 Global 5 and 10 Largest Radiopharmaceuticals in Nuclear Medicine Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE INDUSTRY CHAIN ANALYSIS
4.1 Radiopharmaceuticals in Nuclear Medicine Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Type (2019-2024)
6.3 Global Radiopharmaceuticals in Nuclear Medicine Market Size Market Share by Type (2019-2024)
6.4 Global Radiopharmaceuticals in Nuclear Medicine Price by Type (2019-2024)
7 RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Radiopharmaceuticals in Nuclear Medicine Market Sales by Application (2019-2024)
7.3 Global Radiopharmaceuticals in Nuclear Medicine Market Size (M USD) by Application (2019-2024)
7.4 Global Radiopharmaceuticals in Nuclear Medicine Sales Growth Rate by Application (2019-2024)
8 RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SEGMENTATION BY REGION
8.1 Global Radiopharmaceuticals in Nuclear Medicine Sales by Region
8.1.1 Global Radiopharmaceuticals in Nuclear Medicine Sales by Region
8.1.2 Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Region
8.2 North America
8.2.1 North America Radiopharmaceuticals in Nuclear Medicine Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Radiopharmaceuticals in Nuclear Medicine Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Radiopharmaceuticals in Nuclear Medicine Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Radiopharmaceuticals in Nuclear Medicine Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 KEY COMPANIES PROFILE
9.1 Bracco Imaging S.P.A.
9.1.1 Bracco Imaging S.P.A. Radiopharmaceuticals in Nuclear Medicine Basic Information
9.1.2 Bracco Imaging S.P.A. Radiopharmaceuticals in Nuclear Medicine Product Overview
9.1.3 Bracco Imaging S.P.A. Radiopharmaceuticals in Nuclear Medicine Product Market Performance
9.1.4 Bracco Imaging S.P.A. Business Overview
9.1.5 Bracco Imaging S.P.A. Radiopharmaceuticals in Nuclear Medicine SWOT Analysis
9.1.6 Bracco Imaging S.P.A. Recent Developments
9.2 Cambridge Isotope Laboratories, Inc.
9.2.1 Cambridge Isotope Laboratories, Inc. Radiopharmaceuticals in Nuclear Medicine Basic Information
9.2.2 Cambridge Isotope Laboratories, Inc. Radiopharmaceuticals in Nuclear Medicine Product Overview
9.2.3 Cambridge Isotope Laboratories, Inc. Radiopharmaceuticals in Nuclear Medicine Product Market Performance
9.2.4 Cambridge Isotope Laboratories, Inc. Business Overview
9.2.5 Cambridge Isotope Laboratories, Inc. Radiopharmaceuticals in Nuclear Medicine SWOT Analysis
9.2.6 Cambridge Isotope Laboratories, Inc. Recent Developments
9.3 Cardinal Health, Inc.
9.3.1 Cardinal Health, Inc. Radiopharmaceuticals in Nuclear Medicine Basic Information
9.3.2 Cardinal Health, Inc. Radiopharmaceuticals in Nuclear Medicine Product Overview
9.3.3 Cardinal Health, Inc. Radiopharmaceuticals in Nuclear Medicine Product Market Performance
9.3.4 Cardinal Health, Inc. Radiopharmaceuticals in Nuclear Medicine SWOT Analysis
9.3.5 Cardinal Health, Inc. Business Overview
9.3.6 Cardinal Health, Inc. Recent Developments
9.4 Covidien, Plc
9.4.1 Covidien, Plc Radiopharmaceuticals in Nuclear Medicine Basic Information
9.4.2 Covidien, Plc Radiopharmaceuticals in Nuclear Medicine Product Overview
9.4.3 Covidien, Plc Radiopharmaceuticals in Nuclear Medicine Product Market Performance
9.4.4 Covidien, Plc Business Overview
9.4.5 Covidien, Plc Recent Developments
9.5 Eczacibasi-Monrol
9.5.1 Eczacibasi-Monrol Radiopharmaceuticals in Nuclear Medicine Basic Information
9.5.2 Eczacibasi-Monrol Radiopharmaceuticals in Nuclear Medicine Product Overview
9.5.3 Eczacibasi-Monrol Radiopharmaceuticals in Nuclear Medicine Product Market Performance
9.5.4 Eczacibasi-Monrol Business Overview
9.5.5 Eczacibasi-Monrol Recent Developments
9.6 Fujifilm Holdings Corporation
9.6.1 Fujifilm Holdings Corporation Radiopharmaceuticals in Nuclear Medicine Basic Information
9.6.2 Fujifilm Holdings Corporation Radiopharmaceuticals in Nuclear Medicine Product Overview
9.6.3 Fujifilm Holdings Corporation Radiopharmaceuticals in Nuclear Medicine Product Market Performance
9.6.4 Fujifilm Holdings Corporation Business Overview
9.6.5 Fujifilm Holdings Corporation Recent Developments
9.7 GE Healthcare (Subsidiary Of General Electric Company)
9.7.1 GE Healthcare (Subsidiary Of General Electric Company) Radiopharmaceuticals in Nuclear Medicine Basic Information
9.7.2 GE Healthcare (Subsidiary Of General Electric Company) Radiopharmaceuticals in Nuclear Medicine Product Overview
9.7.3 GE Healthcare (Subsidiary Of General Electric Company) Radiopharmaceuticals in Nuclear Medicine Product Market Performance
9.7.4 GE Healthcare (Subsidiary Of General Electric Company) Business Overview
9.7.5 GE Healthcare (Subsidiary Of General Electric Company) Recent Developments
9.8 IBA Group
9.8.1 IBA Group Radiopharmaceuticals in Nuclear Medicine Basic Information
9.8.2 IBA Group Radiopharmaceuticals in Nuclear Medicine Product Overview
9.8.3 IBA Group Radiopharmaceuticals in Nuclear Medicine Product Market Performance
9.8.4 IBA Group Business Overview
9.8.5 IBA Group Recent Developments
9.9 Isotec, Inc. (Sigma-Aldrich)
9.9.1 Isotec, Inc. (Sigma-Aldrich) Radiopharmaceuticals in Nuclear Medicine Basic Information
9.9.2 Isotec, Inc. (Sigma-Aldrich) Radiopharmaceuticals in Nuclear Medicine Product Overview
9.9.3 Isotec, Inc. (Sigma-Aldrich) Radiopharmaceuticals in Nuclear Medicine Product Market Performance
9.9.4 Isotec, Inc. (Sigma-Aldrich) Business Overview
9.9.5 Isotec, Inc. (Sigma-Aldrich) Recent Developments
9.10 Lantheus Medical Imaging, Inc.
9.10.1 Lantheus Medical Imaging, Inc. Radiopharmaceuticals in Nuclear Medicine Basic Information
9.10.2 Lantheus Medical Imaging, Inc. Radiopharmaceuticals in Nuclear Medicine Product Overview
9.10.3 Lantheus Medical Imaging, Inc. Radiopharmaceuticals in Nuclear Medicine Product Market Performance
9.10.4 Lantheus Medical Imaging, Inc. Business Overview
9.10.5 Lantheus Medical Imaging, Inc. Recent Developments
9.11 Nordion, Inc.
9.11.1 Nordion, Inc. Radiopharmaceuticals in Nuclear Medicine Basic Information
9.11.2 Nordion, Inc. Radiopharmaceuticals in Nuclear Medicine Product Overview
9.11.3 Nordion, Inc. Radiopharmaceuticals in Nuclear Medicine Product Market Performance
9.11.4 Nordion, Inc. Business Overview
9.11.5 Nordion, Inc. Recent Developments
9.12 Ntp Radioisotopes (Pty), Ltd.
9.12.1 Ntp Radioisotopes (Pty), Ltd. Radiopharmaceuticals in Nuclear Medicine Basic Information
9.12.2 Ntp Radioisotopes (Pty), Ltd. Radiopharmaceuticals in Nuclear Medicine Product Overview
9.12.3 Ntp Radioisotopes (Pty), Ltd. Radiopharmaceuticals in Nuclear Medicine Product Market Performance
9.12.4 Ntp Radioisotopes (Pty), Ltd. Business Overview
9.12.5 Ntp Radioisotopes (Pty), Ltd. Recent Developments
9.13 Siemens Healthcare (Subsidiary Of Siemens AG)
9.13.1 Siemens Healthcare (Subsidiary Of Siemens AG) Radiopharmaceuticals in Nuclear Medicine Basic Information
9.13.2 Siemens Healthcare (Subsidiary Of Siemens AG) Radiopharmaceuticals in Nuclear Medicine Product Overview
9.13.3 Siemens Healthcare (Subsidiary Of Siemens AG) Radiopharmaceuticals in Nuclear Medicine Product Market Performance
9.13.4 Siemens Healthcare (Subsidiary Of Siemens AG) Business Overview
9.13.5 Siemens Healthcare (Subsidiary Of Siemens AG) Recent Developments
9.14 Taiyo Nippon Sanso Corporation
9.14.1 Taiyo Nippon Sanso Corporation Radiopharmaceuticals in Nuclear Medicine Basic Information
9.14.2 Taiyo Nippon Sanso Corporation Radiopharmaceuticals in Nuclear Medicine Product Overview
9.14.3 Taiyo Nippon Sanso Corporation Radiopharmaceuticals in Nuclear Medicine Product Market Performance
9.14.4 Taiyo Nippon Sanso Corporation Business Overview
9.14.5 Taiyo Nippon Sanso Corporation Recent Developments
9.15 Urenco Limited
9.15.1 Urenco Limited Radiopharmaceuticals in Nuclear Medicine Basic Information
9.15.2 Urenco Limited Radiopharmaceuticals in Nuclear Medicine Product Overview
9.15.3 Urenco Limited Radiopharmaceuticals in Nuclear Medicine Product Market Performance
9.15.4 Urenco Limited Business Overview
9.15.5 Urenco Limited Recent Developments
9.16 Rotem Industries, Ltd., Inc.
9.16.1 Rotem Industries, Ltd., Inc. Radiopharmaceuticals in Nuclear Medicine Basic Information
9.16.2 Rotem Industries, Ltd., Inc. Radiopharmaceuticals in Nuclear Medicine Product Overview
9.16.3 Rotem Industries, Ltd., Inc. Radiopharmaceuticals in Nuclear Medicine Product Market Performance
9.16.4 Rotem Industries, Ltd., Inc. Business Overview
9.16.5 Rotem Industries, Ltd., Inc. Recent Developments
9.17 Australian Nuclear Association And Technology Organization (ANSTO)
9.17.1 Australian Nuclear Association And Technology Organization (ANSTO) Radiopharmaceuticals in Nuclear Medicine Basic Information
9.17.2 Australian Nuclear Association And Technology Organization (ANSTO) Radiopharmaceuticals in Nuclear Medicine Product Overview
9.17.3 Australian Nuclear Association And Technology Organization (ANSTO) Radiopharmaceuticals in Nuclear Medicine Product Market Performance
9.17.4 Australian Nuclear Association And Technology Organization (ANSTO) Business Overview
9.17.5 Australian Nuclear Association And Technology Organization (ANSTO) Recent Developments
9.18 Board of Radiation And Isotope Technology (BRIT)
9.18.1 Board of Radiation And Isotope Technology (BRIT) Radiopharmaceuticals in Nuclear Medicine Basic Information
9.18.2 Board of Radiation And Isotope Technology (BRIT) Radiopharmaceuticals in Nuclear Medicine Product Overview
9.18.3 Board of Radiation And Isotope Technology (BRIT) Radiopharmaceuticals in Nuclear Medicine Product Market Performance
9.18.4 Board of Radiation And Isotope Technology (BRIT) Business Overview
9.18.5 Board of Radiation And Isotope Technology (BRIT) Recent Developments
9.19 Institute of Atomic Energy Polatom Radioisotope Centre
9.19.1 Institute of Atomic Energy Polatom Radioisotope Centre Radiopharmaceuticals in Nuclear Medicine Basic Information
9.19.2 Institute of Atomic Energy Polatom Radioisotope Centre Radiopharmaceuticals in Nuclear Medicine Product Overview
9.19.3 Institute of Atomic Energy Polatom Radioisotope Centre Radiopharmaceuticals in Nuclear Medicine Product Market Performance
9.19.4 Institute of Atomic Energy Polatom Radioisotope Centre Business Overview
9.19.5 Institute of Atomic Energy Polatom Radioisotope Centre Recent Developments
9.20 Institute of Isotopes Co., Ltd.
9.20.1 Institute of Isotopes Co., Ltd. Radiopharmaceuticals in Nuclear Medicine Basic Information
9.20.2 Institute of Isotopes Co., Ltd. Radiopharmaceuticals in Nuclear Medicine Product Overview
9.20.3 Institute of Isotopes Co., Ltd. Radiopharmaceuticals in Nuclear Medicine Product Market Performance
9.20.4 Institute of Isotopes Co., Ltd. Business Overview
9.20.5 Institute of Isotopes Co., Ltd. Recent Developments
9.21 Institute Of Radioelement (IRE)
9.21.1 Institute Of Radioelement (IRE) Radiopharmaceuticals in Nuclear Medicine Basic Information
9.21.2 Institute Of Radioelement (IRE) Radiopharmaceuticals in Nuclear Medicine Product Overview
9.21.3 Institute Of Radioelement (IRE) Radiopharmaceuticals in Nuclear Medicine Product Market Performance
9.21.4 Institute Of Radioelement (IRE) Business Overview
9.21.5 Institute Of Radioelement (IRE) Recent Developments
10 RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET FORECAST BY REGION
10.1 Global Radiopharmaceuticals in Nuclear Medicine Market Size Forecast
10.2 Global Radiopharmaceuticals in Nuclear Medicine Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Radiopharmaceuticals in Nuclear Medicine Market Size Forecast by Country
10.2.3 Asia Pacific Radiopharmaceuticals in Nuclear Medicine Market Size Forecast by Region
10.2.4 South America Radiopharmaceuticals in Nuclear Medicine Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Radiopharmaceuticals in Nuclear Medicine by Country
11 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2030)
11.1 Global Radiopharmaceuticals in Nuclear Medicine Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of Radiopharmaceuticals in Nuclear Medicine by Type (2025-2030)
11.1.2 Global Radiopharmaceuticals in Nuclear Medicine Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of Radiopharmaceuticals in Nuclear Medicine by Type (2025-2030)
11.2 Global Radiopharmaceuticals in Nuclear Medicine Market Forecast by Application (2025-2030)
11.2.1 Global Radiopharmaceuticals in Nuclear Medicine Sales (Kilotons) Forecast by Application
11.2.2 Global Radiopharmaceuticals in Nuclear Medicine Market Size (M USD) Forecast by Application (2025-2030)
12 CONCLUSION AND KEY FINDINGS
1.1 Market Definition and Statistical Scope of Radiopharmaceuticals in Nuclear Medicine
1.2 Key Market Segments
1.2.1 Radiopharmaceuticals in Nuclear Medicine Segment by Type
1.2.2 Radiopharmaceuticals in Nuclear Medicine Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Radiopharmaceuticals in Nuclear Medicine Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global Radiopharmaceuticals in Nuclear Medicine Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET COMPETITIVE LANDSCAPE
3.1 Global Radiopharmaceuticals in Nuclear Medicine Sales by Manufacturers (2019-2024)
3.2 Global Radiopharmaceuticals in Nuclear Medicine Revenue Market Share by Manufacturers (2019-2024)
3.3 Radiopharmaceuticals in Nuclear Medicine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Radiopharmaceuticals in Nuclear Medicine Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Radiopharmaceuticals in Nuclear Medicine Sales Sites, Area Served, Product Type
3.6 Radiopharmaceuticals in Nuclear Medicine Market Competitive Situation and Trends
3.6.1 Radiopharmaceuticals in Nuclear Medicine Market Concentration Rate
3.6.2 Global 5 and 10 Largest Radiopharmaceuticals in Nuclear Medicine Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE INDUSTRY CHAIN ANALYSIS
4.1 Radiopharmaceuticals in Nuclear Medicine Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Type (2019-2024)
6.3 Global Radiopharmaceuticals in Nuclear Medicine Market Size Market Share by Type (2019-2024)
6.4 Global Radiopharmaceuticals in Nuclear Medicine Price by Type (2019-2024)
7 RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Radiopharmaceuticals in Nuclear Medicine Market Sales by Application (2019-2024)
7.3 Global Radiopharmaceuticals in Nuclear Medicine Market Size (M USD) by Application (2019-2024)
7.4 Global Radiopharmaceuticals in Nuclear Medicine Sales Growth Rate by Application (2019-2024)
8 RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SEGMENTATION BY REGION
8.1 Global Radiopharmaceuticals in Nuclear Medicine Sales by Region
8.1.1 Global Radiopharmaceuticals in Nuclear Medicine Sales by Region
8.1.2 Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Region
8.2 North America
8.2.1 North America Radiopharmaceuticals in Nuclear Medicine Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Radiopharmaceuticals in Nuclear Medicine Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Radiopharmaceuticals in Nuclear Medicine Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Radiopharmaceuticals in Nuclear Medicine Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 KEY COMPANIES PROFILE
9.1 Bracco Imaging S.P.A.
9.1.1 Bracco Imaging S.P.A. Radiopharmaceuticals in Nuclear Medicine Basic Information
9.1.2 Bracco Imaging S.P.A. Radiopharmaceuticals in Nuclear Medicine Product Overview
9.1.3 Bracco Imaging S.P.A. Radiopharmaceuticals in Nuclear Medicine Product Market Performance
9.1.4 Bracco Imaging S.P.A. Business Overview
9.1.5 Bracco Imaging S.P.A. Radiopharmaceuticals in Nuclear Medicine SWOT Analysis
9.1.6 Bracco Imaging S.P.A. Recent Developments
9.2 Cambridge Isotope Laboratories, Inc.
9.2.1 Cambridge Isotope Laboratories, Inc. Radiopharmaceuticals in Nuclear Medicine Basic Information
9.2.2 Cambridge Isotope Laboratories, Inc. Radiopharmaceuticals in Nuclear Medicine Product Overview
9.2.3 Cambridge Isotope Laboratories, Inc. Radiopharmaceuticals in Nuclear Medicine Product Market Performance
9.2.4 Cambridge Isotope Laboratories, Inc. Business Overview
9.2.5 Cambridge Isotope Laboratories, Inc. Radiopharmaceuticals in Nuclear Medicine SWOT Analysis
9.2.6 Cambridge Isotope Laboratories, Inc. Recent Developments
9.3 Cardinal Health, Inc.
9.3.1 Cardinal Health, Inc. Radiopharmaceuticals in Nuclear Medicine Basic Information
9.3.2 Cardinal Health, Inc. Radiopharmaceuticals in Nuclear Medicine Product Overview
9.3.3 Cardinal Health, Inc. Radiopharmaceuticals in Nuclear Medicine Product Market Performance
9.3.4 Cardinal Health, Inc. Radiopharmaceuticals in Nuclear Medicine SWOT Analysis
9.3.5 Cardinal Health, Inc. Business Overview
9.3.6 Cardinal Health, Inc. Recent Developments
9.4 Covidien, Plc
9.4.1 Covidien, Plc Radiopharmaceuticals in Nuclear Medicine Basic Information
9.4.2 Covidien, Plc Radiopharmaceuticals in Nuclear Medicine Product Overview
9.4.3 Covidien, Plc Radiopharmaceuticals in Nuclear Medicine Product Market Performance
9.4.4 Covidien, Plc Business Overview
9.4.5 Covidien, Plc Recent Developments
9.5 Eczacibasi-Monrol
9.5.1 Eczacibasi-Monrol Radiopharmaceuticals in Nuclear Medicine Basic Information
9.5.2 Eczacibasi-Monrol Radiopharmaceuticals in Nuclear Medicine Product Overview
9.5.3 Eczacibasi-Monrol Radiopharmaceuticals in Nuclear Medicine Product Market Performance
9.5.4 Eczacibasi-Monrol Business Overview
9.5.5 Eczacibasi-Monrol Recent Developments
9.6 Fujifilm Holdings Corporation
9.6.1 Fujifilm Holdings Corporation Radiopharmaceuticals in Nuclear Medicine Basic Information
9.6.2 Fujifilm Holdings Corporation Radiopharmaceuticals in Nuclear Medicine Product Overview
9.6.3 Fujifilm Holdings Corporation Radiopharmaceuticals in Nuclear Medicine Product Market Performance
9.6.4 Fujifilm Holdings Corporation Business Overview
9.6.5 Fujifilm Holdings Corporation Recent Developments
9.7 GE Healthcare (Subsidiary Of General Electric Company)
9.7.1 GE Healthcare (Subsidiary Of General Electric Company) Radiopharmaceuticals in Nuclear Medicine Basic Information
9.7.2 GE Healthcare (Subsidiary Of General Electric Company) Radiopharmaceuticals in Nuclear Medicine Product Overview
9.7.3 GE Healthcare (Subsidiary Of General Electric Company) Radiopharmaceuticals in Nuclear Medicine Product Market Performance
9.7.4 GE Healthcare (Subsidiary Of General Electric Company) Business Overview
9.7.5 GE Healthcare (Subsidiary Of General Electric Company) Recent Developments
9.8 IBA Group
9.8.1 IBA Group Radiopharmaceuticals in Nuclear Medicine Basic Information
9.8.2 IBA Group Radiopharmaceuticals in Nuclear Medicine Product Overview
9.8.3 IBA Group Radiopharmaceuticals in Nuclear Medicine Product Market Performance
9.8.4 IBA Group Business Overview
9.8.5 IBA Group Recent Developments
9.9 Isotec, Inc. (Sigma-Aldrich)
9.9.1 Isotec, Inc. (Sigma-Aldrich) Radiopharmaceuticals in Nuclear Medicine Basic Information
9.9.2 Isotec, Inc. (Sigma-Aldrich) Radiopharmaceuticals in Nuclear Medicine Product Overview
9.9.3 Isotec, Inc. (Sigma-Aldrich) Radiopharmaceuticals in Nuclear Medicine Product Market Performance
9.9.4 Isotec, Inc. (Sigma-Aldrich) Business Overview
9.9.5 Isotec, Inc. (Sigma-Aldrich) Recent Developments
9.10 Lantheus Medical Imaging, Inc.
9.10.1 Lantheus Medical Imaging, Inc. Radiopharmaceuticals in Nuclear Medicine Basic Information
9.10.2 Lantheus Medical Imaging, Inc. Radiopharmaceuticals in Nuclear Medicine Product Overview
9.10.3 Lantheus Medical Imaging, Inc. Radiopharmaceuticals in Nuclear Medicine Product Market Performance
9.10.4 Lantheus Medical Imaging, Inc. Business Overview
9.10.5 Lantheus Medical Imaging, Inc. Recent Developments
9.11 Nordion, Inc.
9.11.1 Nordion, Inc. Radiopharmaceuticals in Nuclear Medicine Basic Information
9.11.2 Nordion, Inc. Radiopharmaceuticals in Nuclear Medicine Product Overview
9.11.3 Nordion, Inc. Radiopharmaceuticals in Nuclear Medicine Product Market Performance
9.11.4 Nordion, Inc. Business Overview
9.11.5 Nordion, Inc. Recent Developments
9.12 Ntp Radioisotopes (Pty), Ltd.
9.12.1 Ntp Radioisotopes (Pty), Ltd. Radiopharmaceuticals in Nuclear Medicine Basic Information
9.12.2 Ntp Radioisotopes (Pty), Ltd. Radiopharmaceuticals in Nuclear Medicine Product Overview
9.12.3 Ntp Radioisotopes (Pty), Ltd. Radiopharmaceuticals in Nuclear Medicine Product Market Performance
9.12.4 Ntp Radioisotopes (Pty), Ltd. Business Overview
9.12.5 Ntp Radioisotopes (Pty), Ltd. Recent Developments
9.13 Siemens Healthcare (Subsidiary Of Siemens AG)
9.13.1 Siemens Healthcare (Subsidiary Of Siemens AG) Radiopharmaceuticals in Nuclear Medicine Basic Information
9.13.2 Siemens Healthcare (Subsidiary Of Siemens AG) Radiopharmaceuticals in Nuclear Medicine Product Overview
9.13.3 Siemens Healthcare (Subsidiary Of Siemens AG) Radiopharmaceuticals in Nuclear Medicine Product Market Performance
9.13.4 Siemens Healthcare (Subsidiary Of Siemens AG) Business Overview
9.13.5 Siemens Healthcare (Subsidiary Of Siemens AG) Recent Developments
9.14 Taiyo Nippon Sanso Corporation
9.14.1 Taiyo Nippon Sanso Corporation Radiopharmaceuticals in Nuclear Medicine Basic Information
9.14.2 Taiyo Nippon Sanso Corporation Radiopharmaceuticals in Nuclear Medicine Product Overview
9.14.3 Taiyo Nippon Sanso Corporation Radiopharmaceuticals in Nuclear Medicine Product Market Performance
9.14.4 Taiyo Nippon Sanso Corporation Business Overview
9.14.5 Taiyo Nippon Sanso Corporation Recent Developments
9.15 Urenco Limited
9.15.1 Urenco Limited Radiopharmaceuticals in Nuclear Medicine Basic Information
9.15.2 Urenco Limited Radiopharmaceuticals in Nuclear Medicine Product Overview
9.15.3 Urenco Limited Radiopharmaceuticals in Nuclear Medicine Product Market Performance
9.15.4 Urenco Limited Business Overview
9.15.5 Urenco Limited Recent Developments
9.16 Rotem Industries, Ltd., Inc.
9.16.1 Rotem Industries, Ltd., Inc. Radiopharmaceuticals in Nuclear Medicine Basic Information
9.16.2 Rotem Industries, Ltd., Inc. Radiopharmaceuticals in Nuclear Medicine Product Overview
9.16.3 Rotem Industries, Ltd., Inc. Radiopharmaceuticals in Nuclear Medicine Product Market Performance
9.16.4 Rotem Industries, Ltd., Inc. Business Overview
9.16.5 Rotem Industries, Ltd., Inc. Recent Developments
9.17 Australian Nuclear Association And Technology Organization (ANSTO)
9.17.1 Australian Nuclear Association And Technology Organization (ANSTO) Radiopharmaceuticals in Nuclear Medicine Basic Information
9.17.2 Australian Nuclear Association And Technology Organization (ANSTO) Radiopharmaceuticals in Nuclear Medicine Product Overview
9.17.3 Australian Nuclear Association And Technology Organization (ANSTO) Radiopharmaceuticals in Nuclear Medicine Product Market Performance
9.17.4 Australian Nuclear Association And Technology Organization (ANSTO) Business Overview
9.17.5 Australian Nuclear Association And Technology Organization (ANSTO) Recent Developments
9.18 Board of Radiation And Isotope Technology (BRIT)
9.18.1 Board of Radiation And Isotope Technology (BRIT) Radiopharmaceuticals in Nuclear Medicine Basic Information
9.18.2 Board of Radiation And Isotope Technology (BRIT) Radiopharmaceuticals in Nuclear Medicine Product Overview
9.18.3 Board of Radiation And Isotope Technology (BRIT) Radiopharmaceuticals in Nuclear Medicine Product Market Performance
9.18.4 Board of Radiation And Isotope Technology (BRIT) Business Overview
9.18.5 Board of Radiation And Isotope Technology (BRIT) Recent Developments
9.19 Institute of Atomic Energy Polatom Radioisotope Centre
9.19.1 Institute of Atomic Energy Polatom Radioisotope Centre Radiopharmaceuticals in Nuclear Medicine Basic Information
9.19.2 Institute of Atomic Energy Polatom Radioisotope Centre Radiopharmaceuticals in Nuclear Medicine Product Overview
9.19.3 Institute of Atomic Energy Polatom Radioisotope Centre Radiopharmaceuticals in Nuclear Medicine Product Market Performance
9.19.4 Institute of Atomic Energy Polatom Radioisotope Centre Business Overview
9.19.5 Institute of Atomic Energy Polatom Radioisotope Centre Recent Developments
9.20 Institute of Isotopes Co., Ltd.
9.20.1 Institute of Isotopes Co., Ltd. Radiopharmaceuticals in Nuclear Medicine Basic Information
9.20.2 Institute of Isotopes Co., Ltd. Radiopharmaceuticals in Nuclear Medicine Product Overview
9.20.3 Institute of Isotopes Co., Ltd. Radiopharmaceuticals in Nuclear Medicine Product Market Performance
9.20.4 Institute of Isotopes Co., Ltd. Business Overview
9.20.5 Institute of Isotopes Co., Ltd. Recent Developments
9.21 Institute Of Radioelement (IRE)
9.21.1 Institute Of Radioelement (IRE) Radiopharmaceuticals in Nuclear Medicine Basic Information
9.21.2 Institute Of Radioelement (IRE) Radiopharmaceuticals in Nuclear Medicine Product Overview
9.21.3 Institute Of Radioelement (IRE) Radiopharmaceuticals in Nuclear Medicine Product Market Performance
9.21.4 Institute Of Radioelement (IRE) Business Overview
9.21.5 Institute Of Radioelement (IRE) Recent Developments
10 RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET FORECAST BY REGION
10.1 Global Radiopharmaceuticals in Nuclear Medicine Market Size Forecast
10.2 Global Radiopharmaceuticals in Nuclear Medicine Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Radiopharmaceuticals in Nuclear Medicine Market Size Forecast by Country
10.2.3 Asia Pacific Radiopharmaceuticals in Nuclear Medicine Market Size Forecast by Region
10.2.4 South America Radiopharmaceuticals in Nuclear Medicine Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Radiopharmaceuticals in Nuclear Medicine by Country
11 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2030)
11.1 Global Radiopharmaceuticals in Nuclear Medicine Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of Radiopharmaceuticals in Nuclear Medicine by Type (2025-2030)
11.1.2 Global Radiopharmaceuticals in Nuclear Medicine Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of Radiopharmaceuticals in Nuclear Medicine by Type (2025-2030)
11.2 Global Radiopharmaceuticals in Nuclear Medicine Market Forecast by Application (2025-2030)
11.2.1 Global Radiopharmaceuticals in Nuclear Medicine Sales (Kilotons) Forecast by Application
11.2.2 Global Radiopharmaceuticals in Nuclear Medicine Market Size (M USD) Forecast by Application (2025-2030)
12 CONCLUSION AND KEY FINDINGS
LIST OF TABLES
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Radiopharmaceuticals in Nuclear Medicine Market Size Comparison by Region (M USD)
Table 5. Global Radiopharmaceuticals in Nuclear Medicine Sales (Kilotons) by Manufacturers (2019-2024)
Table 6. Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Manufacturers (2019-2024)
Table 7. Global Radiopharmaceuticals in Nuclear Medicine Revenue (M USD) by Manufacturers (2019-2024)
Table 8. Global Radiopharmaceuticals in Nuclear Medicine Revenue Share by Manufacturers (2019-2024)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Radiopharmaceuticals in Nuclear Medicine as of 2022)
Table 10. Global Market Radiopharmaceuticals in Nuclear Medicine Average Price (USD/Ton) of Key Manufacturers (2019-2024)
Table 11. Manufacturers Radiopharmaceuticals in Nuclear Medicine Sales Sites and Area Served
Table 12. Manufacturers Radiopharmaceuticals in Nuclear Medicine Product Type
Table 13. Global Radiopharmaceuticals in Nuclear Medicine Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of Radiopharmaceuticals in Nuclear Medicine
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Radiopharmaceuticals in Nuclear Medicine Market Challenges
Table 22. Global Radiopharmaceuticals in Nuclear Medicine Sales by Type (Kilotons)
Table 23. Global Radiopharmaceuticals in Nuclear Medicine Market Size by Type (M USD)
Table 24. Global Radiopharmaceuticals in Nuclear Medicine Sales (Kilotons) by Type (2019-2024)
Table 25. Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Type (2019-2024)
Table 26. Global Radiopharmaceuticals in Nuclear Medicine Market Size (M USD) by Type (2019-2024)
Table 27. Global Radiopharmaceuticals in Nuclear Medicine Market Size Share by Type (2019-2024)
Table 28. Global Radiopharmaceuticals in Nuclear Medicine Price (USD/Ton) by Type (2019-2024)
Table 29. Global Radiopharmaceuticals in Nuclear Medicine Sales (Kilotons) by Application
Table 30. Global Radiopharmaceuticals in Nuclear Medicine Market Size by Application
Table 31. Global Radiopharmaceuticals in Nuclear Medicine Sales by Application (2019-2024) & (Kilotons)
Table 32. Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Application (2019-2024)
Table 33. Global Radiopharmaceuticals in Nuclear Medicine Sales by Application (2019-2024) & (M USD)
Table 34. Global Radiopharmaceuticals in Nuclear Medicine Market Share by Application (2019-2024)
Table 35. Global Radiopharmaceuticals in Nuclear Medicine Sales Growth Rate by Application (2019-2024)
Table 36. Global Radiopharmaceuticals in Nuclear Medicine Sales by Region (2019-2024) & (Kilotons)
Table 37. Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Region (2019-2024)
Table 38. North America Radiopharmaceuticals in Nuclear Medicine Sales by Country (2019-2024) & (Kilotons)
Table 39. Europe Radiopharmaceuticals in Nuclear Medicine Sales by Country (2019-2024) & (Kilotons)
Table 40. Asia Pacific Radiopharmaceuticals in Nuclear Medicine Sales by Region (2019-2024) & (Kilotons)
Table 41. South America Radiopharmaceuticals in Nuclear Medicine Sales by Country (2019-2024) & (Kilotons)
Table 42. Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Sales by Region (2019-2024) & (Kilotons)
Table 43. Bracco Imaging S.P.A. Radiopharmaceuticals in Nuclear Medicine Basic Information
Table 44. Bracco Imaging S.P.A. Radiopharmaceuticals in Nuclear Medicine Product Overview
Table 45. Bracco Imaging S.P.A. Radiopharmaceuticals in Nuclear Medicine Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 46. Bracco Imaging S.P.A. Business Overview
Table 47. Bracco Imaging S.P.A. Radiopharmaceuticals in Nuclear Medicine SWOT Analysis
Table 48. Bracco Imaging S.P.A. Recent Developments
Table 49. Cambridge Isotope Laboratories, Inc. Radiopharmaceuticals in Nuclear Medicine Basic Information
Table 50. Cambridge Isotope Laboratories, Inc. Radiopharmaceuticals in Nuclear Medicine Product Overview
Table 51. Cambridge Isotope Laboratories, Inc. Radiopharmaceuticals in Nuclear Medicine Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 52. Cambridge Isotope Laboratories, Inc. Business Overview
Table 53. Cambridge Isotope Laboratories, Inc. Radiopharmaceuticals in Nuclear Medicine SWOT Analysis
Table 54. Cambridge Isotope Laboratories, Inc. Recent Developments
Table 55. Cardinal Health, Inc. Radiopharmaceuticals in Nuclear Medicine Basic Information
Table 56. Cardinal Health, Inc. Radiopharmaceuticals in Nuclear Medicine Product Overview
Table 57. Cardinal Health, Inc. Radiopharmaceuticals in Nuclear Medicine Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 58. Cardinal Health, Inc. Radiopharmaceuticals in Nuclear Medicine SWOT Analysis
Table 59. Cardinal Health, Inc. Business Overview
Table 60. Cardinal Health, Inc. Recent Developments
Table 61. Covidien, Plc Radiopharmaceuticals in Nuclear Medicine Basic Information
Table 62. Covidien, Plc Radiopharmaceuticals in Nuclear Medicine Product Overview
Table 63. Covidien, Plc Radiopharmaceuticals in Nuclear Medicine Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 64. Covidien, Plc Business Overview
Table 65. Covidien, Plc Recent Developments
Table 66. Eczacibasi-Monrol Radiopharmaceuticals in Nuclear Medicine Basic Information
Table 67. Eczacibasi-Monrol Radiopharmaceuticals in Nuclear Medicine Product Overview
Table 68. Eczacibasi-Monrol Radiopharmaceuticals in Nuclear Medicine Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 69. Eczacibasi-Monrol Business Overview
Table 70. Eczacibasi-Monrol Recent Developments
Table 71. Fujifilm Holdings Corporation Radiopharmaceuticals in Nuclear Medicine Basic Information
Table 72. Fujifilm Holdings Corporation Radiopharmaceuticals in Nuclear Medicine Product Overview
Table 73. Fujifilm Holdings Corporation Radiopharmaceuticals in Nuclear Medicine Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 74. Fujifilm Holdings Corporation Business Overview
Table 75. Fujifilm Holdings Corporation Recent Developments
Table 76. GE Healthcare (Subsidiary Of General Electric Company) Radiopharmaceuticals in Nuclear Medicine Basic Information
Table 77. GE Healthcare (Subsidiary Of General Electric Company) Radiopharmaceuticals in Nuclear Medicine Product Overview
Table 78. GE Healthcare (Subsidiary Of General Electric Company) Radiopharmaceuticals in Nuclear Medicine Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 79. GE Healthcare (Subsidiary Of General Electric Company) Business Overview
Table 80. GE Healthcare (Subsidiary Of General Electric Company) Recent Developments
Table 81. IBA Group Radiopharmaceuticals in Nuclear Medicine Basic Information
Table 82. IBA Group Radiopharmaceuticals in Nuclear Medicine Product Overview
Table 83. IBA Group Radiopharmaceuticals in Nuclear Medicine Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 84. IBA Group Business Overview
Table 85. IBA Group Recent Developments
Table 86. Isotec, Inc. (Sigma-Aldrich) Radiopharmaceuticals in Nuclear Medicine Basic Information
Table 87. Isotec, Inc. (Sigma-Aldrich) Radiopharmaceuticals in Nuclear Medicine Product Overview
Table 88. Isotec, Inc. (Sigma-Aldrich) Radiopharmaceuticals in Nuclear Medicine Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 89. Isotec, Inc. (Sigma-Aldrich) Business Overview
Table 90. Isotec, Inc. (Sigma-Aldrich) Recent Developments
Table 91. Lantheus Medical Imaging, Inc. Radiopharmaceuticals in Nuclear Medicine Basic Information
Table 92. Lantheus Medical Imaging, Inc. Radiopharmaceuticals in Nuclear Medicine Product Overview
Table 93. Lantheus Medical Imaging, Inc. Radiopharmaceuticals in Nuclear Medicine Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 94. Lantheus Medical Imaging, Inc. Business Overview
Table 95. Lantheus Medical Imaging, Inc. Recent Developments
Table 96. Nordion, Inc. Radiopharmaceuticals in Nuclear Medicine Basic Information
Table 97. Nordion, Inc. Radiopharmaceuticals in Nuclear Medicine Product Overview
Table 98. Nordion, Inc. Radiopharmaceuticals in Nuclear Medicine Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 99. Nordion, Inc. Business Overview
Table 100. Nordion, Inc. Recent Developments
Table 101. Ntp Radioisotopes (Pty), Ltd. Radiopharmaceuticals in Nuclear Medicine Basic Information
Table 102. Ntp Radioisotopes (Pty), Ltd. Radiopharmaceuticals in Nuclear Medicine Product Overview
Table 103. Ntp Radioisotopes (Pty), Ltd. Radiopharmaceuticals in Nuclear Medicine Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 104. Ntp Radioisotopes (Pty), Ltd. Business Overview
Table 105. Ntp Radioisotopes (Pty), Ltd. Recent Developments
Table 106. Siemens Healthcare (Subsidiary Of Siemens AG) Radiopharmaceuticals in Nuclear Medicine Basic Information
Table 107. Siemens Healthcare (Subsidiary Of Siemens AG) Radiopharmaceuticals in Nuclear Medicine Product Overview
Table 108. Siemens Healthcare (Subsidiary Of Siemens AG) Radiopharmaceuticals in Nuclear Medicine Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 109. Siemens Healthcare (Subsidiary Of Siemens AG) Business Overview
Table 110. Siemens Healthcare (Subsidiary Of Siemens AG) Recent Developments
Table 111. Taiyo Nippon Sanso Corporation Radiopharmaceuticals in Nuclear Medicine Basic Information
Table 112. Taiyo Nippon Sanso Corporation Radiopharmaceuticals in Nuclear Medicine Product Overview
Table 113. Taiyo Nippon Sanso Corporation Radiopharmaceuticals in Nuclear Medicine Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 114. Taiyo Nippon Sanso Corporation Business Overview
Table 115. Taiyo Nippon Sanso Corporation Recent Developments
Table 116. Urenco Limited Radiopharmaceuticals in Nuclear Medicine Basic Information
Table 117. Urenco Limited Radiopharmaceuticals in Nuclear Medicine Product Overview
Table 118. Urenco Limited Radiopharmaceuticals in Nuclear Medicine Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 119. Urenco Limited Business Overview
Table 120. Urenco Limited Recent Developments
Table 121. Rotem Industries, Ltd., Inc. Radiopharmaceuticals in Nuclear Medicine Basic Information
Table 122. Rotem Industries, Ltd., Inc. Radiopharmaceuticals in Nuclear Medicine Product Overview
Table 123. Rotem Industries, Ltd., Inc. Radiopharmaceuticals in Nuclear Medicine Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 124. Rotem Industries, Ltd., Inc. Business Overview
Table 125. Rotem Industries, Ltd., Inc. Recent Developments
Table 126. Australian Nuclear Association And Technology Organization (ANSTO) Radiopharmaceuticals in Nuclear Medicine Basic Information
Table 127. Australian Nuclear Association And Technology Organization (ANSTO) Radiopharmaceuticals in Nuclear Medicine Product Overview
Table 128. Australian Nuclear Association And Technology Organization (ANSTO) Radiopharmaceuticals in Nuclear Medicine Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 129. Australian Nuclear Association And Technology Organization (ANSTO) Business Overview
Table 130. Australian Nuclear Association And Technology Organization (ANSTO) Recent Developments
Table 131. Board of Radiation And Isotope Technology (BRIT) Radiopharmaceuticals in Nuclear Medicine Basic Information
Table 132. Board of Radiation And Isotope Technology (BRIT) Radiopharmaceuticals in Nuclear Medicine Product Overview
Table 133. Board of Radiation And Isotope Technology (BRIT) Radiopharmaceuticals in Nuclear Medicine Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 134. Board of Radiation And Isotope Technology (BRIT) Business Overview
Table 135. Board of Radiation And Isotope Technology (BRIT) Recent Developments
Table 136. Institute of Atomic Energy Polatom Radioisotope Centre Radiopharmaceuticals in Nuclear Medicine Basic Information
Table 137. Institute of Atomic Energy Polatom Radioisotope Centre Radiopharmaceuticals in Nuclear Medicine Product Overview
Table 138. Institute of Atomic Energy Polatom Radioisotope Centre Radiopharmaceuticals in Nuclear Medicine Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 139. Institute of Atomic Energy Polatom Radioisotope Centre Business Overview
Table 140. Institute of Atomic Energy Polatom Radioisotope Centre Recent Developments
Table 141. Institute of Isotopes Co., Ltd. Radiopharmaceuticals in Nuclear Medicine Basic Information
Table 142. Institute of Isotopes Co., Ltd. Radiopharmaceuticals in Nuclear Medicine Product Overview
Table 143. Institute of Isotopes Co., Ltd. Radiopharmaceuticals in Nuclear Medicine Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 144. Institute of Isotopes Co., Ltd. Business Overview
Table 145. Institute of Isotopes Co., Ltd. Recent Developments
Table 146. Institute Of Radioelement (IRE) Radiopharmaceuticals in Nuclear Medicine Basic Information
Table 147. Institute Of Radioelement (IRE) Radiopharmaceuticals in Nuclear Medicine Product Overview
Table 148. Institute Of Radioelement (IRE) Radiopharmaceuticals in Nuclear Medicine Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 149. Institute Of Radioelement (IRE) Business Overview
Table 150. Institute Of Radioelement (IRE) Recent Developments
Table 151. Global Radiopharmaceuticals in Nuclear Medicine Sales Forecast by Region (2025-2030) & (Kilotons)
Table 152. Global Radiopharmaceuticals in Nuclear Medicine Market Size Forecast by Region (2025-2030) & (M USD)
Table 153. North America Radiopharmaceuticals in Nuclear Medicine Sales Forecast by Country (2025-2030) & (Kilotons)
Table 154. North America Radiopharmaceuticals in Nuclear Medicine Market Size Forecast by Country (2025-2030) & (M USD)
Table 155. Europe Radiopharmaceuticals in Nuclear Medicine Sales Forecast by Country (2025-2030) & (Kilotons)
Table 156. Europe Radiopharmaceuticals in Nuclear Medicine Market Size Forecast by Country (2025-2030) & (M USD)
Table 157. Asia Pacific Radiopharmaceuticals in Nuclear Medicine Sales Forecast by Region (2025-2030) & (Kilotons)
Table 158. Asia Pacific Radiopharmaceuticals in Nuclear Medicine Market Size Forecast by Region (2025-2030) & (M USD)
Table 159. South America Radiopharmaceuticals in Nuclear Medicine Sales Forecast by Country (2025-2030) & (Kilotons)
Table 160. South America Radiopharmaceuticals in Nuclear Medicine Market Size Forecast by Country (2025-2030) & (M USD)
Table 161. Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Consumption Forecast by Country (2025-2030) & (Units)
Table 162. Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Market Size Forecast by Country (2025-2030) & (M USD)
Table 163. Global Radiopharmaceuticals in Nuclear Medicine Sales Forecast by Type (2025-2030) & (Kilotons)
Table 164. Global Radiopharmaceuticals in Nuclear Medicine Market Size Forecast by Type (2025-2030) & (M USD)
Table 165. Global Radiopharmaceuticals in Nuclear Medicine Price Forecast by Type (2025-2030) & (USD/Ton)
Table 166. Global Radiopharmaceuticals in Nuclear Medicine Sales (Kilotons) Forecast by Application (2025-2030)
Table 167. Global Radiopharmaceuticals in Nuclear Medicine Market Size Forecast by Application (2025-2030) & (M USD)
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Radiopharmaceuticals in Nuclear Medicine Market Size Comparison by Region (M USD)
Table 5. Global Radiopharmaceuticals in Nuclear Medicine Sales (Kilotons) by Manufacturers (2019-2024)
Table 6. Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Manufacturers (2019-2024)
Table 7. Global Radiopharmaceuticals in Nuclear Medicine Revenue (M USD) by Manufacturers (2019-2024)
Table 8. Global Radiopharmaceuticals in Nuclear Medicine Revenue Share by Manufacturers (2019-2024)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Radiopharmaceuticals in Nuclear Medicine as of 2022)
Table 10. Global Market Radiopharmaceuticals in Nuclear Medicine Average Price (USD/Ton) of Key Manufacturers (2019-2024)
Table 11. Manufacturers Radiopharmaceuticals in Nuclear Medicine Sales Sites and Area Served
Table 12. Manufacturers Radiopharmaceuticals in Nuclear Medicine Product Type
Table 13. Global Radiopharmaceuticals in Nuclear Medicine Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of Radiopharmaceuticals in Nuclear Medicine
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Radiopharmaceuticals in Nuclear Medicine Market Challenges
Table 22. Global Radiopharmaceuticals in Nuclear Medicine Sales by Type (Kilotons)
Table 23. Global Radiopharmaceuticals in Nuclear Medicine Market Size by Type (M USD)
Table 24. Global Radiopharmaceuticals in Nuclear Medicine Sales (Kilotons) by Type (2019-2024)
Table 25. Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Type (2019-2024)
Table 26. Global Radiopharmaceuticals in Nuclear Medicine Market Size (M USD) by Type (2019-2024)
Table 27. Global Radiopharmaceuticals in Nuclear Medicine Market Size Share by Type (2019-2024)
Table 28. Global Radiopharmaceuticals in Nuclear Medicine Price (USD/Ton) by Type (2019-2024)
Table 29. Global Radiopharmaceuticals in Nuclear Medicine Sales (Kilotons) by Application
Table 30. Global Radiopharmaceuticals in Nuclear Medicine Market Size by Application
Table 31. Global Radiopharmaceuticals in Nuclear Medicine Sales by Application (2019-2024) & (Kilotons)
Table 32. Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Application (2019-2024)
Table 33. Global Radiopharmaceuticals in Nuclear Medicine Sales by Application (2019-2024) & (M USD)
Table 34. Global Radiopharmaceuticals in Nuclear Medicine Market Share by Application (2019-2024)
Table 35. Global Radiopharmaceuticals in Nuclear Medicine Sales Growth Rate by Application (2019-2024)
Table 36. Global Radiopharmaceuticals in Nuclear Medicine Sales by Region (2019-2024) & (Kilotons)
Table 37. Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Region (2019-2024)
Table 38. North America Radiopharmaceuticals in Nuclear Medicine Sales by Country (2019-2024) & (Kilotons)
Table 39. Europe Radiopharmaceuticals in Nuclear Medicine Sales by Country (2019-2024) & (Kilotons)
Table 40. Asia Pacific Radiopharmaceuticals in Nuclear Medicine Sales by Region (2019-2024) & (Kilotons)
Table 41. South America Radiopharmaceuticals in Nuclear Medicine Sales by Country (2019-2024) & (Kilotons)
Table 42. Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Sales by Region (2019-2024) & (Kilotons)
Table 43. Bracco Imaging S.P.A. Radiopharmaceuticals in Nuclear Medicine Basic Information
Table 44. Bracco Imaging S.P.A. Radiopharmaceuticals in Nuclear Medicine Product Overview
Table 45. Bracco Imaging S.P.A. Radiopharmaceuticals in Nuclear Medicine Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 46. Bracco Imaging S.P.A. Business Overview
Table 47. Bracco Imaging S.P.A. Radiopharmaceuticals in Nuclear Medicine SWOT Analysis
Table 48. Bracco Imaging S.P.A. Recent Developments
Table 49. Cambridge Isotope Laboratories, Inc. Radiopharmaceuticals in Nuclear Medicine Basic Information
Table 50. Cambridge Isotope Laboratories, Inc. Radiopharmaceuticals in Nuclear Medicine Product Overview
Table 51. Cambridge Isotope Laboratories, Inc. Radiopharmaceuticals in Nuclear Medicine Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 52. Cambridge Isotope Laboratories, Inc. Business Overview
Table 53. Cambridge Isotope Laboratories, Inc. Radiopharmaceuticals in Nuclear Medicine SWOT Analysis
Table 54. Cambridge Isotope Laboratories, Inc. Recent Developments
Table 55. Cardinal Health, Inc. Radiopharmaceuticals in Nuclear Medicine Basic Information
Table 56. Cardinal Health, Inc. Radiopharmaceuticals in Nuclear Medicine Product Overview
Table 57. Cardinal Health, Inc. Radiopharmaceuticals in Nuclear Medicine Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 58. Cardinal Health, Inc. Radiopharmaceuticals in Nuclear Medicine SWOT Analysis
Table 59. Cardinal Health, Inc. Business Overview
Table 60. Cardinal Health, Inc. Recent Developments
Table 61. Covidien, Plc Radiopharmaceuticals in Nuclear Medicine Basic Information
Table 62. Covidien, Plc Radiopharmaceuticals in Nuclear Medicine Product Overview
Table 63. Covidien, Plc Radiopharmaceuticals in Nuclear Medicine Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 64. Covidien, Plc Business Overview
Table 65. Covidien, Plc Recent Developments
Table 66. Eczacibasi-Monrol Radiopharmaceuticals in Nuclear Medicine Basic Information
Table 67. Eczacibasi-Monrol Radiopharmaceuticals in Nuclear Medicine Product Overview
Table 68. Eczacibasi-Monrol Radiopharmaceuticals in Nuclear Medicine Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 69. Eczacibasi-Monrol Business Overview
Table 70. Eczacibasi-Monrol Recent Developments
Table 71. Fujifilm Holdings Corporation Radiopharmaceuticals in Nuclear Medicine Basic Information
Table 72. Fujifilm Holdings Corporation Radiopharmaceuticals in Nuclear Medicine Product Overview
Table 73. Fujifilm Holdings Corporation Radiopharmaceuticals in Nuclear Medicine Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 74. Fujifilm Holdings Corporation Business Overview
Table 75. Fujifilm Holdings Corporation Recent Developments
Table 76. GE Healthcare (Subsidiary Of General Electric Company) Radiopharmaceuticals in Nuclear Medicine Basic Information
Table 77. GE Healthcare (Subsidiary Of General Electric Company) Radiopharmaceuticals in Nuclear Medicine Product Overview
Table 78. GE Healthcare (Subsidiary Of General Electric Company) Radiopharmaceuticals in Nuclear Medicine Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 79. GE Healthcare (Subsidiary Of General Electric Company) Business Overview
Table 80. GE Healthcare (Subsidiary Of General Electric Company) Recent Developments
Table 81. IBA Group Radiopharmaceuticals in Nuclear Medicine Basic Information
Table 82. IBA Group Radiopharmaceuticals in Nuclear Medicine Product Overview
Table 83. IBA Group Radiopharmaceuticals in Nuclear Medicine Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 84. IBA Group Business Overview
Table 85. IBA Group Recent Developments
Table 86. Isotec, Inc. (Sigma-Aldrich) Radiopharmaceuticals in Nuclear Medicine Basic Information
Table 87. Isotec, Inc. (Sigma-Aldrich) Radiopharmaceuticals in Nuclear Medicine Product Overview
Table 88. Isotec, Inc. (Sigma-Aldrich) Radiopharmaceuticals in Nuclear Medicine Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 89. Isotec, Inc. (Sigma-Aldrich) Business Overview
Table 90. Isotec, Inc. (Sigma-Aldrich) Recent Developments
Table 91. Lantheus Medical Imaging, Inc. Radiopharmaceuticals in Nuclear Medicine Basic Information
Table 92. Lantheus Medical Imaging, Inc. Radiopharmaceuticals in Nuclear Medicine Product Overview
Table 93. Lantheus Medical Imaging, Inc. Radiopharmaceuticals in Nuclear Medicine Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 94. Lantheus Medical Imaging, Inc. Business Overview
Table 95. Lantheus Medical Imaging, Inc. Recent Developments
Table 96. Nordion, Inc. Radiopharmaceuticals in Nuclear Medicine Basic Information
Table 97. Nordion, Inc. Radiopharmaceuticals in Nuclear Medicine Product Overview
Table 98. Nordion, Inc. Radiopharmaceuticals in Nuclear Medicine Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 99. Nordion, Inc. Business Overview
Table 100. Nordion, Inc. Recent Developments
Table 101. Ntp Radioisotopes (Pty), Ltd. Radiopharmaceuticals in Nuclear Medicine Basic Information
Table 102. Ntp Radioisotopes (Pty), Ltd. Radiopharmaceuticals in Nuclear Medicine Product Overview
Table 103. Ntp Radioisotopes (Pty), Ltd. Radiopharmaceuticals in Nuclear Medicine Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 104. Ntp Radioisotopes (Pty), Ltd. Business Overview
Table 105. Ntp Radioisotopes (Pty), Ltd. Recent Developments
Table 106. Siemens Healthcare (Subsidiary Of Siemens AG) Radiopharmaceuticals in Nuclear Medicine Basic Information
Table 107. Siemens Healthcare (Subsidiary Of Siemens AG) Radiopharmaceuticals in Nuclear Medicine Product Overview
Table 108. Siemens Healthcare (Subsidiary Of Siemens AG) Radiopharmaceuticals in Nuclear Medicine Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 109. Siemens Healthcare (Subsidiary Of Siemens AG) Business Overview
Table 110. Siemens Healthcare (Subsidiary Of Siemens AG) Recent Developments
Table 111. Taiyo Nippon Sanso Corporation Radiopharmaceuticals in Nuclear Medicine Basic Information
Table 112. Taiyo Nippon Sanso Corporation Radiopharmaceuticals in Nuclear Medicine Product Overview
Table 113. Taiyo Nippon Sanso Corporation Radiopharmaceuticals in Nuclear Medicine Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 114. Taiyo Nippon Sanso Corporation Business Overview
Table 115. Taiyo Nippon Sanso Corporation Recent Developments
Table 116. Urenco Limited Radiopharmaceuticals in Nuclear Medicine Basic Information
Table 117. Urenco Limited Radiopharmaceuticals in Nuclear Medicine Product Overview
Table 118. Urenco Limited Radiopharmaceuticals in Nuclear Medicine Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 119. Urenco Limited Business Overview
Table 120. Urenco Limited Recent Developments
Table 121. Rotem Industries, Ltd., Inc. Radiopharmaceuticals in Nuclear Medicine Basic Information
Table 122. Rotem Industries, Ltd., Inc. Radiopharmaceuticals in Nuclear Medicine Product Overview
Table 123. Rotem Industries, Ltd., Inc. Radiopharmaceuticals in Nuclear Medicine Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 124. Rotem Industries, Ltd., Inc. Business Overview
Table 125. Rotem Industries, Ltd., Inc. Recent Developments
Table 126. Australian Nuclear Association And Technology Organization (ANSTO) Radiopharmaceuticals in Nuclear Medicine Basic Information
Table 127. Australian Nuclear Association And Technology Organization (ANSTO) Radiopharmaceuticals in Nuclear Medicine Product Overview
Table 128. Australian Nuclear Association And Technology Organization (ANSTO) Radiopharmaceuticals in Nuclear Medicine Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 129. Australian Nuclear Association And Technology Organization (ANSTO) Business Overview
Table 130. Australian Nuclear Association And Technology Organization (ANSTO) Recent Developments
Table 131. Board of Radiation And Isotope Technology (BRIT) Radiopharmaceuticals in Nuclear Medicine Basic Information
Table 132. Board of Radiation And Isotope Technology (BRIT) Radiopharmaceuticals in Nuclear Medicine Product Overview
Table 133. Board of Radiation And Isotope Technology (BRIT) Radiopharmaceuticals in Nuclear Medicine Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 134. Board of Radiation And Isotope Technology (BRIT) Business Overview
Table 135. Board of Radiation And Isotope Technology (BRIT) Recent Developments
Table 136. Institute of Atomic Energy Polatom Radioisotope Centre Radiopharmaceuticals in Nuclear Medicine Basic Information
Table 137. Institute of Atomic Energy Polatom Radioisotope Centre Radiopharmaceuticals in Nuclear Medicine Product Overview
Table 138. Institute of Atomic Energy Polatom Radioisotope Centre Radiopharmaceuticals in Nuclear Medicine Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 139. Institute of Atomic Energy Polatom Radioisotope Centre Business Overview
Table 140. Institute of Atomic Energy Polatom Radioisotope Centre Recent Developments
Table 141. Institute of Isotopes Co., Ltd. Radiopharmaceuticals in Nuclear Medicine Basic Information
Table 142. Institute of Isotopes Co., Ltd. Radiopharmaceuticals in Nuclear Medicine Product Overview
Table 143. Institute of Isotopes Co., Ltd. Radiopharmaceuticals in Nuclear Medicine Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 144. Institute of Isotopes Co., Ltd. Business Overview
Table 145. Institute of Isotopes Co., Ltd. Recent Developments
Table 146. Institute Of Radioelement (IRE) Radiopharmaceuticals in Nuclear Medicine Basic Information
Table 147. Institute Of Radioelement (IRE) Radiopharmaceuticals in Nuclear Medicine Product Overview
Table 148. Institute Of Radioelement (IRE) Radiopharmaceuticals in Nuclear Medicine Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 149. Institute Of Radioelement (IRE) Business Overview
Table 150. Institute Of Radioelement (IRE) Recent Developments
Table 151. Global Radiopharmaceuticals in Nuclear Medicine Sales Forecast by Region (2025-2030) & (Kilotons)
Table 152. Global Radiopharmaceuticals in Nuclear Medicine Market Size Forecast by Region (2025-2030) & (M USD)
Table 153. North America Radiopharmaceuticals in Nuclear Medicine Sales Forecast by Country (2025-2030) & (Kilotons)
Table 154. North America Radiopharmaceuticals in Nuclear Medicine Market Size Forecast by Country (2025-2030) & (M USD)
Table 155. Europe Radiopharmaceuticals in Nuclear Medicine Sales Forecast by Country (2025-2030) & (Kilotons)
Table 156. Europe Radiopharmaceuticals in Nuclear Medicine Market Size Forecast by Country (2025-2030) & (M USD)
Table 157. Asia Pacific Radiopharmaceuticals in Nuclear Medicine Sales Forecast by Region (2025-2030) & (Kilotons)
Table 158. Asia Pacific Radiopharmaceuticals in Nuclear Medicine Market Size Forecast by Region (2025-2030) & (M USD)
Table 159. South America Radiopharmaceuticals in Nuclear Medicine Sales Forecast by Country (2025-2030) & (Kilotons)
Table 160. South America Radiopharmaceuticals in Nuclear Medicine Market Size Forecast by Country (2025-2030) & (M USD)
Table 161. Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Consumption Forecast by Country (2025-2030) & (Units)
Table 162. Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Market Size Forecast by Country (2025-2030) & (M USD)
Table 163. Global Radiopharmaceuticals in Nuclear Medicine Sales Forecast by Type (2025-2030) & (Kilotons)
Table 164. Global Radiopharmaceuticals in Nuclear Medicine Market Size Forecast by Type (2025-2030) & (M USD)
Table 165. Global Radiopharmaceuticals in Nuclear Medicine Price Forecast by Type (2025-2030) & (USD/Ton)
Table 166. Global Radiopharmaceuticals in Nuclear Medicine Sales (Kilotons) Forecast by Application (2025-2030)
Table 167. Global Radiopharmaceuticals in Nuclear Medicine Market Size Forecast by Application (2025-2030) & (M USD)
LIST OF FIGURES
Figure 1. Product Picture of Radiopharmaceuticals in Nuclear Medicine
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Radiopharmaceuticals in Nuclear Medicine Market Size (M USD), 2019-2030
Figure 5. Global Radiopharmaceuticals in Nuclear Medicine Market Size (M USD) (2019-2030)
Figure 6. Global Radiopharmaceuticals in Nuclear Medicine Sales (Kilotons) & (2019-2030)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Radiopharmaceuticals in Nuclear Medicine Market Size by Country (M USD)
Figure 11. Radiopharmaceuticals in Nuclear Medicine Sales Share by Manufacturers in 2023
Figure 12. Global Radiopharmaceuticals in Nuclear Medicine Revenue Share by Manufacturers in 2023
Figure 13. Radiopharmaceuticals in Nuclear Medicine Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market Radiopharmaceuticals in Nuclear Medicine Average Price (USD/Ton) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by Radiopharmaceuticals in Nuclear Medicine Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global Radiopharmaceuticals in Nuclear Medicine Market Share by Type
Figure 18. Sales Market Share of Radiopharmaceuticals in Nuclear Medicine by Type (2019-2024)
Figure 19. Sales Market Share of Radiopharmaceuticals in Nuclear Medicine by Type in 2023
Figure 20. Market Size Share of Radiopharmaceuticals in Nuclear Medicine by Type (2019-2024)
Figure 21. Market Size Market Share of Radiopharmaceuticals in Nuclear Medicine by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Radiopharmaceuticals in Nuclear Medicine Market Share by Application
Figure 24. Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Application (2019-2024)
Figure 25. Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Application in 2023
Figure 26. Global Radiopharmaceuticals in Nuclear Medicine Market Share by Application (2019-2024)
Figure 27. Global Radiopharmaceuticals in Nuclear Medicine Market Share by Application in 2023
Figure 28. Global Radiopharmaceuticals in Nuclear Medicine Sales Growth Rate by Application (2019-2024)
Figure 29. Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Region (2019-2024)
Figure 30. North America Radiopharmaceuticals in Nuclear Medicine Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 31. North America Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Country in 2023
Figure 32. U.S. Radiopharmaceuticals in Nuclear Medicine Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 33. Canada Radiopharmaceuticals in Nuclear Medicine Sales (Kilotons) and Growth Rate (2019-2024)
Figure 34. Mexico Radiopharmaceuticals in Nuclear Medicine Sales (Units) and Growth Rate (2019-2024)
Figure 35. Europe Radiopharmaceuticals in Nuclear Medicine Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 36. Europe Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Country in 2023
Figure 37. Germany Radiopharmaceuticals in Nuclear Medicine Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 38. France Radiopharmaceuticals in Nuclear Medicine Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 39. U.K. Radiopharmaceuticals in Nuclear Medicine Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 40. Italy Radiopharmaceuticals in Nuclear Medicine Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 41. Russia Radiopharmaceuticals in Nuclear Medicine Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 42. Asia Pacific Radiopharmaceuticals in Nuclear Medicine Sales and Growth Rate (Kilotons)
Figure 43. Asia Pacific Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Region in 2023
Figure 44. China Radiopharmaceuticals in Nuclear Medicine Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 45. Japan Radiopharmaceuticals in Nuclear Medicine Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 46. South Korea Radiopharmaceuticals in Nuclear Medicine Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 47. India Radiopharmaceuticals in Nuclear Medicine Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 48. Southeast Asia Radiopharmaceuticals in Nuclear Medicine Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 49. South America Radiopharmaceuticals in Nuclear Medicine Sales and Growth Rate (Kilotons)
Figure 50. South America Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Country in 2023
Figure 51. Brazil Radiopharmaceuticals in Nuclear Medicine Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 52. Argentina Radiopharmaceuticals in Nuclear Medicine Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 53. Columbia Radiopharmaceuticals in Nuclear Medicine Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 54. Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Sales and Growth Rate (Kilotons)
Figure 55. Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Region in 2023
Figure 56. Saudi Arabia Radiopharmaceuticals in Nuclear Medicine Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 57. UAE Radiopharmaceuticals in Nuclear Medicine Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 58. Egypt Radiopharmaceuticals in Nuclear Medicine Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 59. Nigeria Radiopharmaceuticals in Nuclear Medicine Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 60. South Africa Radiopharmaceuticals in Nuclear Medicine Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 61. Global Radiopharmaceuticals in Nuclear Medicine Sales Forecast by Volume (2019-2030) & (Kilotons)
Figure 62. Global Radiopharmaceuticals in Nuclear Medicine Market Size Forecast by Value (2019-2030) & (M USD)
Figure 63. Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share Forecast by Type (2025-2030)
Figure 64. Global Radiopharmaceuticals in Nuclear Medicine Market Share Forecast by Type (2025-2030)
Figure 65. Global Radiopharmaceuticals in Nuclear Medicine Sales Forecast by Application (2025-2030)
Figure 66. Global Radiopharmaceuticals in Nuclear Medicine Market Share Forecast by Application (2025-2030)
Figure 1. Product Picture of Radiopharmaceuticals in Nuclear Medicine
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Radiopharmaceuticals in Nuclear Medicine Market Size (M USD), 2019-2030
Figure 5. Global Radiopharmaceuticals in Nuclear Medicine Market Size (M USD) (2019-2030)
Figure 6. Global Radiopharmaceuticals in Nuclear Medicine Sales (Kilotons) & (2019-2030)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Radiopharmaceuticals in Nuclear Medicine Market Size by Country (M USD)
Figure 11. Radiopharmaceuticals in Nuclear Medicine Sales Share by Manufacturers in 2023
Figure 12. Global Radiopharmaceuticals in Nuclear Medicine Revenue Share by Manufacturers in 2023
Figure 13. Radiopharmaceuticals in Nuclear Medicine Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market Radiopharmaceuticals in Nuclear Medicine Average Price (USD/Ton) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by Radiopharmaceuticals in Nuclear Medicine Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global Radiopharmaceuticals in Nuclear Medicine Market Share by Type
Figure 18. Sales Market Share of Radiopharmaceuticals in Nuclear Medicine by Type (2019-2024)
Figure 19. Sales Market Share of Radiopharmaceuticals in Nuclear Medicine by Type in 2023
Figure 20. Market Size Share of Radiopharmaceuticals in Nuclear Medicine by Type (2019-2024)
Figure 21. Market Size Market Share of Radiopharmaceuticals in Nuclear Medicine by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Radiopharmaceuticals in Nuclear Medicine Market Share by Application
Figure 24. Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Application (2019-2024)
Figure 25. Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Application in 2023
Figure 26. Global Radiopharmaceuticals in Nuclear Medicine Market Share by Application (2019-2024)
Figure 27. Global Radiopharmaceuticals in Nuclear Medicine Market Share by Application in 2023
Figure 28. Global Radiopharmaceuticals in Nuclear Medicine Sales Growth Rate by Application (2019-2024)
Figure 29. Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Region (2019-2024)
Figure 30. North America Radiopharmaceuticals in Nuclear Medicine Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 31. North America Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Country in 2023
Figure 32. U.S. Radiopharmaceuticals in Nuclear Medicine Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 33. Canada Radiopharmaceuticals in Nuclear Medicine Sales (Kilotons) and Growth Rate (2019-2024)
Figure 34. Mexico Radiopharmaceuticals in Nuclear Medicine Sales (Units) and Growth Rate (2019-2024)
Figure 35. Europe Radiopharmaceuticals in Nuclear Medicine Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 36. Europe Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Country in 2023
Figure 37. Germany Radiopharmaceuticals in Nuclear Medicine Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 38. France Radiopharmaceuticals in Nuclear Medicine Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 39. U.K. Radiopharmaceuticals in Nuclear Medicine Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 40. Italy Radiopharmaceuticals in Nuclear Medicine Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 41. Russia Radiopharmaceuticals in Nuclear Medicine Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 42. Asia Pacific Radiopharmaceuticals in Nuclear Medicine Sales and Growth Rate (Kilotons)
Figure 43. Asia Pacific Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Region in 2023
Figure 44. China Radiopharmaceuticals in Nuclear Medicine Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 45. Japan Radiopharmaceuticals in Nuclear Medicine Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 46. South Korea Radiopharmaceuticals in Nuclear Medicine Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 47. India Radiopharmaceuticals in Nuclear Medicine Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 48. Southeast Asia Radiopharmaceuticals in Nuclear Medicine Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 49. South America Radiopharmaceuticals in Nuclear Medicine Sales and Growth Rate (Kilotons)
Figure 50. South America Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Country in 2023
Figure 51. Brazil Radiopharmaceuticals in Nuclear Medicine Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 52. Argentina Radiopharmaceuticals in Nuclear Medicine Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 53. Columbia Radiopharmaceuticals in Nuclear Medicine Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 54. Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Sales and Growth Rate (Kilotons)
Figure 55. Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Region in 2023
Figure 56. Saudi Arabia Radiopharmaceuticals in Nuclear Medicine Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 57. UAE Radiopharmaceuticals in Nuclear Medicine Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 58. Egypt Radiopharmaceuticals in Nuclear Medicine Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 59. Nigeria Radiopharmaceuticals in Nuclear Medicine Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 60. South Africa Radiopharmaceuticals in Nuclear Medicine Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 61. Global Radiopharmaceuticals in Nuclear Medicine Sales Forecast by Volume (2019-2030) & (Kilotons)
Figure 62. Global Radiopharmaceuticals in Nuclear Medicine Market Size Forecast by Value (2019-2030) & (M USD)
Figure 63. Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share Forecast by Type (2025-2030)
Figure 64. Global Radiopharmaceuticals in Nuclear Medicine Market Share Forecast by Type (2025-2030)
Figure 65. Global Radiopharmaceuticals in Nuclear Medicine Sales Forecast by Application (2025-2030)
Figure 66. Global Radiopharmaceuticals in Nuclear Medicine Market Share Forecast by Application (2025-2030)
